Considerations of the Department of Psychogeriatrics of ABP on the approval and clinical use of donanemabe in Alzheimer's disease by ANVISA
DOI:
https://doi.org/10.25118/2763-9037.2025.v15.1464Keywords:
donanemabe, Alzheimer`s disease, dementiaAbstract
The Department of Psychogeriatrics, after critical analysis of pivotal studies and recent scientific literature, issues the following considerations on the approval and clinical use of donanemab, a monoclonal antibody targeting beta-amyloid, for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD).
Downloads
Metrics
References
1. Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A, Greenberg SM, Hendrix SB, Petersen RC, Weiner M, Salloway S, Cummings J. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2025;12:1-18. https://doi.org/10.1016/j.tjpad.2025.100150 PMid:40155270
2. Agência Nacional de Vigilância Sanitária. Kisunla (donanemabe): novo registro [Internet]. Brasília: ANVISA; 2025. [citado 2025 Abr. 27]. Disponível em: https://www.gov.br/anvisa
3. Ebell MH, Barry HC, Baduni K, Grasso G. Clinically important benefits and harms of monoclonal antibodies targeting amyloid for the treatment of Alzheimer disease: a systematic review and meta-analysis. Ann Fam Med. 2024;22(1):50-8. https://doi.org/10.1370/afm.3050 PMid:38253509 PMCid:PMC11233076
4. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks JD, Wessels AM, Shcherbinin S, Wang H, Nery ESM, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM. Donanemab in early symptomatic Alzheimer's disease. JAMA. 2023;330(10):512-27. https://doi.org/10.1136/dtb.2024.000020 PMid: 38580400
5. Mintun M, Ritchie CW, Solomon P, Sims JR, Salloway S, Hansson O, Apostolova LG, Zimmer JA, Evans CD, Lu M, Ardayfio PA, Sparks JD, Wessels AM, Shcherbinin S, Wang H, Nery ESM, Collins EC, Dennehy EB, Brooks DA, Skovronsky DM. Donanemab treatment effects on amyloid and tau PET imaging biomarkers in early symptomatic Alzheimer's disease: results from TRAILBLAZER-ALZ 2. Alzheimers Dement. 2023;19(S24): e082733. https://doi.org/10.1002/alz.082733
6. Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784. https://doi.org/10.3389/fnins.2024.1326784 PMid:38312931 PMCid:PMC10834650
7. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023 Nov 2;146(11):4414-24. https://doi.org/10.1093/brain/awad188 PMid:37280110 PMCid:PMC10629981
8. Klein EG, Schroeder K, Wessels AM, Phipps A, Japha M, Schilling T, Zimmer JA. How donanemab data address the coverage with evidence development questions. Alzheimers Dement. 2024 Apr;20(4):3127-40. https://doi.org/10.1002/alz.13700 PMid:38323738 PMCid:PMC11032520
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Tania Correa de Toledo Ferraz Alves, Ricardo Barcelos Ferreira, Lucas Alves Pereira, Rodrigo Nicolato, Maria Alice de Vilhena Toledo, Juliano Victor Albuquerque Luna, Alan Goulart Bussolo, Carlos Clayton Torres Aguiar, Aline Kives Berger, Gilberto Sousa Alves, Nairton Lopes Cruz, Alberto Stoppe Junior, Marcus Kiiti Borges, Marcelo Allevato , Claudio Meneghello Martins, Antônio Geraldo da Silva
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
